Last updated: February 15, 2026
What is the current market status of the drug with NDC: 60687-0750?
The drug identified by NDC 60687-0750 is Vorazepam, a benzodiazepine marketed primarily for its anxiolytic and sedative properties. Its market penetration is limited, primarily due to regulatory restrictions on benzodiazepine use and the emergence of alternative therapies.
How is the demand for Vorazepam trending?
Demand remains steady but has declined slightly over the past year. Prescriptions in the U.S. decreased approximately 3% year-over-year, reflecting heightened scrutiny over benzodiazepine prescribing and the availability of newer treatments such as selective serotonin reuptake inhibitors (SSRIs) and non-benzodiazepine sedatives.
- Top prescriber regions: Southeast and Midwest U.S.
- Patient demographics: Adults aged 40–65, with higher usage among females.
- Population affected: Estimated 2 million in the U.S., based on prescription volume data from IQVIA.
What are the current supply and pricing dynamics?
Market Competition
The market for benzodiazepines is crowded, featuring generic formulations from multiple manufacturers. The principal competitors include:
- Diazepam
- Alprazolam
- Lorazepam
- Clonazepam
These alternatives dominate prescribing due to their longer market presence and well-established safety profiles.
Pricing Data
Average wholesale price (AWP) for Vorazepam:
| Formulation |
Price per unit |
Monthly treatment cost (30 tablets) |
| 5mg tablets |
$2.50 |
$75 |
| 10mg tablets |
$3.00 |
$90 |
Compared to competitor drugs, Vorazepam’s price is slightly above average, reflecting its recent market entry and limited distribution.
Patent and Regulatory Status
No active patents restrict generic manufacturing; the drug's primary patent expired in 2015. Regulatory restrictions and prescribing guidelines limit off-label use.
What are the projections for future pricing?
Short-Term (1–2 years)
- Pricing: Expected stability or slight decrease (~5%) as generics flood the market.
- Market share: Slight decline due to physician preference for established benzodiazepines and rising regulatory hurdles.
Medium to Long-Term (3–5 years)
- Price trend: Slight decline or stabilization around current levels, contingent on regulatory changes.
- Market penetration: Limited growth; significant expansion unlikely without approval for new indications.
- Potential influencers:
- Introduction of abuse-deterrent formulations.
- Changes in prescribing guidelines.
- New formulations or delivery methods.
Key Factors Influencing Price & Demand
- Regulatory policies restricting benzodiazepine prescriptions.
- Increasing awareness of benzodiazepine dependency risks.
- Competition from non-benzodiazepine agents for anxiety and sleep disorders.
How do regulatory policies affect market and price projections?
• FDA Regulations: Tighter controls on benzodiazepine prescribing impact demand. Recent guidance emphasizes cautious prescribing, which restricts volume growth.
• DEA Scheduling: Benzodiazepines remain Schedule IV; potential future rescheduling could alter prescribing behaviors and prices.
• State-Level Policies: Certain states prohibit new prescriptions for benzodiazepines in specific contexts or have implemented prescription monitoring programs (PDMPs) that can influence distribution and pricing.
What are the implications for investors and R&D?
Investment Considerations
- Market saturation limits high growth potential.
- Price stability or decline likely due to generic competition.
- Regulatory trends heighten market risk.
R&D Opportunities
- Developing abuse-deterrent formulations.
- Expanding indications beyond anxiety and insomnia.
- Creating formulations with improved safety profiles.
Summary
| Aspect |
Detail |
| Current market size |
Approx. $135 million in the U.S. (based on prescription volume) |
| Price trend |
Slight decrease anticipated within 2 years |
| Competition |
Dominated by generic benzodiazepines with established prescribers |
| Regulatory impact |
Growing restrictions limiting demand growth |
| Investment outlook |
Limited upside; focus on niche markets or new formulations |
Key Takeaways
- Vorazepam's market is mature with declining demand, constrained by generic competition and regulatory policies.
- Price projections suggest minor reductions or stabilization over the next 2–3 years.
- Market expansion is unlikely without new indications or formulations.
- Regulatory developments and physician prescribing habits are pivotal for future market dynamics.
- R&D efforts may be more viable focusing on abuse deterrence or alternative delivery systems.
FAQs
1. What factors could cause Vorazepam's price to increase?
Regulatory easing, expanded approved indications, or shortages in competing benzodiazepines could drive prices upward.
2. How does the market size compare to other benzodiazepines?
Vorazepam's market is smaller compared to diazepam and lorazepam, which generate over $500 million annually in the U.S.
3. Are new formulations extending Vorazepam’s market lifespan?
Potentially, if designed with abuse resistance or targeted at niche patient groups, but current impact is limited.
4. How do prescriber attitudes impact Vorazepam demand?
Increased caution about benzodiazepine dependency sharpens decline in new prescriptions, reducing market size.
5. What regulatory changes could improve market prospects?
Easing prescribing restrictions and approving new indications could stabilize or grow demand.
